Topical Delivery of Avastin to the Posterior Segment of the Eye In Vivo Using Annexin A5‐associated Liposomes

• DOI: 10.1002/smll.201303433
• Publication Date: 2014-03-05T07:48:39Z
• Authors: Benjamin M. Davis; Eduardo M. Normando; Li Guo; Lisa A. Turner; Shereen Nizari; Paul O'Shea; Stephen E. Moss; Satyanarayana Som...; M. Francesca Cord...
• Keywords: Intravitreal administration

Effective delivery to the retina is presently one of most challenging areas in drug development ophthalmology, due anatomical barriers preventing entry therapeutic substances. Intraocular injection only route administration for large protein therapeutics, including anti‐Vascular Endothelial Growth Factors Lucentis (ranibizumab) and Avastin (bevacizumab). Anti‐VEGFs have revolutionised management age‐related macular degeneration increasing indications use as sight‐saving therapies diabetes retinal vascular disease. Considerable resources been allocated develop non‐invasive ocular systems. It has suggested that anionic phospholipid binding annexin A5, may a role delivery. In present study we demonstrate, using combination vitro vivo assays, presence A5 can significantly enhance uptake transcytosis liposomal carrier systems across corneal epithelial barriers. This system employed deliver physiologically significant concentrations posterior rat eye (127 ng/g) rabbit (18 after topical application. Our observations provide evidence suggest mediated endocytosis associated lipidic vehicles biological barriers, which implications.